Click on image to view larger version.

Figure 1 Relative risk for major adverse cardiovascular events (MACE) up to nine months in randomized trials of the TAXUS paclitaxel-eluting stent; MACE is composite occurrence of cardiovascular death, myocardial infarction, or target vessel revascularization (see text). MR = moderate release; SR = slow release.